BMC Psychiatry
August 5, 2026
Xiang Liu, Yuanzhi He, Lifeng Li et al.
Abstract Introduction Major depressive disorder (MDD) is characterized by dysfunction in higher-order cortical regions involved in emotional and cognitive processes; however, its neurobiological basis remains unclear. Pharmacological treatments, including esketamine and sertraline, produce rapid antidepressant effects. We investigated the local intrinsic neural dynamics underlying these...
Danish medical journal
August 4, 2026
Maj Vinberg
This narrative review examines barriers to Danish patients' timely access to new treatments for treatment-resistant depression, focusing on controversies around esketamine. Delays arise from regulatory complexity, economic constraints and scientific debate over novel psychotropics. The review advocates evidence-based, faster implementation pathways for new treatments to alleviate the overall...
Therapeutic Advances in Psychopharmacology
August 1, 2026
Pierre-Michel Llorca, Anne Sauvaget, Emilie Olié et al.
Background: Major depressive disorder (MDD) is highly prevalent and associated with significant disability and mortality. Treatment-resistant depression (TRD), defined as inadequate response to ⩾2 antidepressant lines, remains a major therapeutic challenge. Esketamine nasal spray, approved in 2019 for TRD, demonstrated efficacy and safety in randomized trials, but real-world evidence remains...
Journal of Affective Disorders
August 1, 2026
Ching-Hua Julie Lee, Yunzhe Qian, Weiqun Yu et al.
This study evaluated the long-term comparative effectiveness and safety of esketamine versus injectable ketamine and esketamine versus oral antidepressants for major depressive disorder (MDD). This emulated target trial utilized observational data from a cohort of U.S. adults with MDD between 2018 and 2024. Patients were categorized into those receiving esketamine, injectable R,S-ketamine, and...
Journal of Affective Disorders
August 1, 2026
João Paulo Atidio, Rodrigo Simonini Delfino, Igor Saque Garios et al.
Ketamine and esketamine have been increasingly used as adjunctive treatments for treatment-resistant depression (TRD), yet evidence on pharmacological interactions with commonly prescribed psychotropic medications remains limited. This study evaluated the association between concomitant lamotrigine, lithium, and benzodiazepine use and antidepressant outcomes during subcutaneous esketamine...
Frontiers in Psychiatry
July 30, 2026
Muhammad Abbas, Bruno Kallas, Max Garris
This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms. She experienced a relapse after a reduction in her maintenance treatment in conjunction with psychosocial stressors, but improved once again after returning to her induction regimen. She tolerated the...
Annals of Clinical Psychiatry
July 29, 2026
Neha Ather, Mashal Zahid, Mohammad Hassan et al.
Background Depression remains a leading cause of disability and suicide worldwide, with treatment-resistant depression (TRD) affecting nearly 30% of individuals diagnosed with major depressive disorder. Esketamine nasal spray (NS) and quetiapine extended-release (XR) are both approved as adjunctive therapies for TRD; however, direct head-to-head comparisons are limited. Method A systematic...
J Clin Psychopharmacol
July 28, 2026
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.
npj Mental Health Research
July 27, 2026
Jennifer Swainson, P. Grewal, S. Polard et al.
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with...
Pharmacology, biochemistry, and behavior
July 26, 2026
Peng Zhang, Mengyu Wu, Keke Zhang et al.
Esketamine has been approved for the treatment of treatment-resistant depression. However, there is an unmet clinical need to extend the duration of esketamine's action to reduce the high recurrence rate after drug withdrawal and the potential side effects of repeated esketamine use. Here, we found that increasing extracellular signal-regulated kinase (ERK) activity by pharmacologically...